Endothelin receptor antagonists in cardiology clinical trials

被引：16

作者：

Neunteufl, T ^{[1
]}

Berger, R ^{[1
]}

Pacher, R ^{[1
]}

机构：

[1] Univ Vienna, Sch Med, Dept Cardiol, A-1090 Vienna, Austria

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2002年 / 11卷 / 03期

关键词：

arterial hypertension; clinical trials; congestive heart failure; coronary artery disease; endothelin receptor antagonist; pulmonary hypertension;

D O I：

10.1517/13543784.11.3.431

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Endothelin-1 (ET-1) is enhanced and has been demonstrated to be a prognostic marker in patients with advanced stages of heart failure, acute ischaemic syndromes, myocardial infarction and pulmonary hypertension. Activation of the endothelin (ET) system is associated with adverse haemodynamic consequences in patients with congestive heart failure and results in coronary vasoconstriction in patients with coronary artery disease (CAD). Moreover, ET-1 raises blood pressure,induces vascular and myocardial hypertrophy and acts as the natural counterpart of nitric oxide (NO), which exerts vasodilating, antithrombotic and antiproliferative effects. This article reviews recently completed and ongoing clinical trials examining the effects of ET receptor antagonists in patients with heart failure, CAD, arterial hypertension and pulmonary hypertension.

引用

页码：431 / 443

页数：13

共 91 条

[1]

*ABB LAB, 2001, MERR LYNCH GLOB HEAL

[2]

Barst RJ, 2000, CIRCULATION, V102, P427

[3] SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN [J].

BARST, RJ ;

RUBIN, LJ ;

MCGOON, MD ;

CALDWELL, EJ ;

LONG, WA ;

LEVY, PS .

ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :409-415

[4] ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension [J].

Barton, M ;

d'Uscio, LV ;

Shaw, S ;

Meyer, P ;

Moreau, P ;

Lüscher, TF .

HYPERTENSION, 1998, 31 (01) :499-504

[5]

Berger R, 2001, CIRCULATION, V103, P981

[6] Endothelin in cardiovascular disease: From atherosclerosis to heart failure [J].

Best, PJM ;

Lerman, A .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 :S61-S63

[7] RELEASE OF ENDOTHELIN FROM THE PORCINE AORTA - INHIBITION BY ENDOTHELIUM-DERIVED NITRIC-OXIDE [J].

BOULANGER, C ;

LUSCHER, TF .

JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (02) :587-590

[8] Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors - Role of suppression of endogenous endothelin secretion [J].

Brunner, F ;

Kukovetz, WR .

CIRCULATION, 1996, 94 (07) :1752-1761

[9]

Burrell KM, 2000, J PHARMACOL EXP THER, V292, P449

[10] Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure [J].

Cannan, CR ;

Burnett, JC ;

Lerman, A .

CIRCULATION, 1996, 93 (04) :646-651

← 1 2 3 4 5 6 7 8 9 10 →